BETHLEHEM, Pa., July 14, 2011 /PRNewswire/ — The Renal
Therapies Division of B. Braun Medical Inc. (B. Braun)
announced today the availability of the Plasmat™ Futura
System for H.E.L.P.® LDL Apheresis therapy. This
addition to B. Braun’s existing H.E.L.P.® therapy
provides a more easy-to-use system for clinicians to administer the
most effective care to patients with severe
hypercholesterolemia.
(Logo:
http://photos.prnewswire.com/prnh/20081022/NYW008LOGO)
H.E.L.P.® therapy (Heparin-induced
Extracorporeal Lipoprotein Precipitation) is a blood cleansing
procedure for the long-term management of patients with severe,
congenital lipid disorders that cannot be adequately treated with
diet modification or drugs.
“The addition of the Plasmat™ Futura Apheresis system to
our existing H.E.L.P.® therapy system exemplifies B.
Braun’s commitment to providing clinicians with innovative systems
that help get their jobs done with more convenience and
flexibility,” said Samuel Amory, Vice President, Medical Technology
Division for B. Braun Medical Inc. “LDL Apheresis therapy is a
complex therapy and the Plasmat™ Futura helps to streamline
treatment.”
Designed to be compact and easy to use, the Plasmat™
Futura system provides built-in convenience for maximum mobility
and flexibility. In addition, the Plasmat™ Futura features a
state-of-the-art user interface and does not require an on-site
water treatment system, both improvements over the previous
H.E.L.P.® system.
“The Plasmat™ Futura LDL Apheresis machine is the first
promising procedure that has drastically cut my LDL by more than 60
percent,” said Patrika Wallach-Knickle, a patient of Massachusetts
General Hospital. “All it requires is a commitment of two mornings
a month to sit and relax while the machine does the work. This
small commitment is nothing compared to th
‘/>”/>
